{"id":954,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2017-09-20","marketCap":290.196,"name":"Celcuity Inc","phone":"17633920767.0","outstanding":22.09,"symbol":"CELC","website":"https://www.celcuity.com/","industry":"Biotechnology"},"price":12.59,"year":2023,"month":11,"day":18,"weekday":"Saturday","title":"Impact of demographic shifts and population trends on Celcuity Inc stock and sector","date":"2023-11-18","url":"/posts/2023/11/18/CELC","content":[{"section":"1. Changing aging population","text":"As the global population continues to age, there is an increased prevalence of age-related diseases such as cancer. This presents a significant opportunity for Celcuity Inc, as the company specializes in developing innovative diagnostic tests for cancer. The growing demand for these tests can potentially drive the growth of Celcuity Inc's stock and the sector as a whole."},{"section":"2. Increasing focus on personalized medicine","text":"Demographic shifts have also led to a greater focus on personalized medicine, tailoring treatments based on individual patient characteristics. Celcuity Inc's unique approach to cancer diagnostics, which focuses on identifying the activated cell signaling pathways driving individual patients' tumors, aligns well with this trend. The increasing demand for personalized medicine can potentially benefit Celcuity Inc's stock and the sector by driving sales of their diagnostic tests."},{"section":"3. Geographic distribution and market expansion","text":"Demographic shifts can also impact the geographic distribution of the population, with certain regions experiencing higher population growth rates than others. Celcuity Inc and its sector may benefit from such demographic shifts if they lead to an expansion of the market in regions with increasing populations. This can potentially drive revenue growth and positively impact Celcuity Inc's stock."},{"section":"4. Impact of healthcare access and affordability","text":"Population trends, such as increasing healthcare access and affordability, can also influence the demand for Celcuity Inc's products and services. If more individuals have access to healthcare and can afford cancer diagnostic tests, it can lead to an increase in the company's customer base and revenue. However, limitations in healthcare access and affordability can negatively impact the growth prospects of the sector and Celcuity Inc's stock."},{"section":"5. Technological advancements and adoption","text":"Demographic shifts can drive the adoption of new technologies and advancements in the healthcare sector. Celcuity Inc and its sector can benefit from the increased adoption of their innovative diagnostic tests as healthcare systems embrace technological advancements. This can contribute to revenue growth and potentially impact Celcuity Inc's stock positively."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1699977040,"headline":"Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript","id":123868983,"image":"https://media.zenfs.com/en/insidermonkey.com/85718ae4f2b98e3af008e0676dc5e478","symbol":"CELC","publisher":"Yahoo","summary":"Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Greetings, and welcome to the Celcuity Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It […]","url":"https://finance.yahoo.com/news/celcuity-inc-nasdaq-celc-q3-155040596.html"},{"category":"company","date":1699929710,"headline":"Q3 2023 Celcuity Inc Earnings Call","id":123855353,"image":"","symbol":"CELC","publisher":"Yahoo","summary":"Q3 2023 Celcuity Inc Earnings Call","url":"https://finance.yahoo.com/news/q3-2023-celcuity-inc-earnings-024150502.html"},{"category":"company","date":1699890889,"headline":"Celcuity Inc (CELC) Reports Q3 2023 Financial Results and Strategic Developments","id":123855354,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"CELC","publisher":"Yahoo","summary":"Increased R\u0026D Expenses Drive Net Loss Expansion; Cash Position Remains Strong","url":"https://finance.yahoo.com/news/celcuity-inc-celc-reports-q3-155449629.html"},{"category":"company","date":1699879265,"headline":"Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript","id":123836817,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"CELC","publisher":"SeekingAlpha","summary":"Celcuity Inc. (NASDAQ:NASDAQ:CELC) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ETCompany ParticipantsMaria Yonkoski - Investor Relations,...","url":"https://seekingalpha.com/article/4651262-celcuity-inc-celc-q3-2023-earnings-call-transcript"},{"category":"company","date":1699877100,"headline":"Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates","id":123831956,"image":"https://media.zenfs.com/en/globenewswire.com/5d6beb04817f108eee902f94066e26e6","symbol":"CELC","publisher":"Yahoo","summary":"Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) for planned Phase 1b/2 clinical trialRaised $50 million in private placement sale of equityManagement to host webcast and conference call today, November 13, 2023, at 8:00 a.m. ET MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) --","url":"https://finance.yahoo.com/news/celcuity-inc-reports-third-quarter-120500248.html"},{"category":"company","date":1699869060,"headline":"Celcuity Q3 Non-GAAP EPS of -$0.78 misses by $0.25","id":123841518,"image":"","symbol":"CELC","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3210074112"},{"category":"company","date":1699869060,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Inogen (INGN) and Celcuity (CELC)","id":123836052,"image":"","symbol":"CELC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3210074801"},{"category":"company","date":1699868460,"headline":"Analysts Conflicted on These Healthcare Names: Inogen (INGN), Eli Lilly \u0026 Co (LLY) and Celcuity (CELC)","id":123836053,"image":"","symbol":"CELC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3210060406"},{"category":"company","date":1699864260,"headline":"Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Celcuity (CELC)","id":123837567,"image":"","symbol":"CELC","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3209969060"},{"category":"company","date":1699855860,"headline":"Celcuity reports Q3 non-GAAP EPS (78c), consensus (68c)","id":123841523,"image":"","symbol":"CELC","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3209816655"},{"category":"company","date":1699854120,"headline":"Earnings Scheduled For November 13, 2023","id":123833726,"image":"","symbol":"CELC","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3209792462"},{"category":"company","date":1699273800,"headline":"Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call","id":123657260,"image":"https://media.zenfs.com/en/globenewswire.com/5d6beb04817f108eee902f94066e26e6","symbol":"CELC","publisher":"Yahoo","summary":"MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To part","url":"https://finance.yahoo.com/news/celcuity-inc-schedules-release-third-123000265.html"}]}